Voting Results from BioNTech’s Annual General Meeting 2022
June 01 2022 - 1:15PM
- Shareholders reappointed Helmut Jeggle as Chairman of the
Supervisory Board
- Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will
complement the existing Supervisory Board to reflect company
growth
- Shareholders followed the proposal of the Management Board and
Supervisory Board and resolved to pay a special cash dividend of
€2.00 per ordinary share
MAINZ, GERMANY, June 1, 2022 (GLOBE
NEWSWIRE) — At the Annual General Meeting (“AGM”) of
BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held today,
June 1, 2022, shareholders voted to reappoint Helmut Jeggle as a
member of the Supervisory Board with a majority of 96.44 per cent.
In a meeting following the AGM, the Supervisory Board re-elected
Helmut Jeggle as its Chairman. Shareholders also appointed two
additional Supervisory Board members, Prof. Dr. Anja Morawietz and
Prof. Dr. Rudolf Staudigl with a majority of 99.85 per cent and
99.86 per cent respectively. All three members will serve in their
roles until the AGM 2026.
In addition, the shareholders passed the
proposal of the Management Board and Supervisory Board and resolved
to pay a special cash dividend of €2.00 per ordinary share
(including those held in the form of ADSs). This corresponds to
approximately €484.2 million, based on the shares outstanding
and entitled to dividends as of May 30, 2022, being the record date
relevant for determination.
“Over the past two years, BioNTech has developed
into a fully integrated biotech company with a diversified clinical
pipeline, including several late-staged product candidates. We want
our shareholders to participate in our strong 2021 performance via
a special cash dividend and a share repurchase program. This is in
line with BioNTech’s capital allocation strategy and the company’s
commitment to delivering shareholder value,” said Helmut
Jeggle, Chairman of the Supervisory Board of BioNTech.
“With Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl, we
are gaining further expertise in finance, governance and
international markets, which will complement the existing skillset
of the Board. I am grateful for the opportunity to continue to
serve this company as Chairman of the Supervisory Board.”
Helmut Jeggle has served as Chairman of
BioNTech’s Supervisory Board since 2008. He is Chief Executive
Officer and founder of Salvia GmbH, a family office which focuses
on investments in deep tech and science. From 2015 to 2021, he
served as General Partner at ATHOS KG, the Strüngmann family
office. Prior to that, he was Head of Direct Investments at ATHOS
Service GmbH and held various positions with Hexal AG. Helmut
Jeggle is a member of Supervisory Boards in Germany and
internationally, including 4SC AG, AiCuris AG and tonies SE.
Prof. Dr. Anja Morawietz is Professor of
External Accounting and General Business Administration at the
Nuremberg University of Applied Sciences Georg Simon Ohm. She has
in-depth expertise in accounting and auditing. In her research, she
covers financial and sustainability reporting as well as
developments in corporate governance.
Prof. Dr. Rudolf Staudigl is an independent
consultant and member of the Supervisory Board of TÜV Süd AG. He
has extensive knowledge of production, science, and international
markets, with a focus on China and India. He also has a deep
understanding of biotechnology products having served for many
years as Chairman of the Board of Directors of Wacker Chemie AG, an
internationally active chemical company.
Jens Holstein, CFO of BioNTech,
said: “We want to redeploy our financial resources in a meaningful
way and thus prepare the ground for the company’s future growth. In
the years to come, we intend to invest especially into our R&D
engine and expect to spend for 2022 alone between €1.4 billion and
€1.5 billion in our current R&D initiatives. At the same time,
we intend to accelerate further growth inorganically, for example
with synergistic acquisitions and in-licensing deals.”
BioNTech’s rapid growth in the past financial
year has significantly increased the workload of its committees. As
this is also to be expected for the financial year 2022, the
shareholders passed the Management Board and Supervisory Board’s
proposal to remunerate committee work separately. An ordinary
committee member will receive an additional annual remuneration of
€5,000 per committee in the future and committee chairs will be
remunerated with €15,000 per year, with the exception of the Audit
Committee chair who receives €30,000 per year.
About BioNTech
Biopharmaceutical New Technologies is a next
generation immunotherapy company pioneering novel therapies for
cancer and other serious diseases. The Company exploits a wide
array of computational discovery and therapeutic drug platforms for
the rapid development of novel biopharmaceuticals. Its broad
portfolio of oncology product candidates includes individualized
and off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor T cells, bi-specific checkpoint immuno-modulators,
targeted cancer antibodies and small molecules. Based on its deep
expertise in mRNA vaccine development and in-house manufacturing
capabilities, BioNTech and its collaborators are developing
multiple mRNA vaccine candidates for a range of infectious diseases
alongside its diverse oncology pipeline. BioNTech has established a
broad set of relationships with multiple global pharmaceutical
collaborators, including Genmab, Sanofi, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For
more information, please visit www.BioNTech.de.
BioNTech Forward-looking Statements
This press release contains “forward-looking
statements” of BioNTech within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements may include, but may not be limited to, statements
concerning: BioNTech’s 2021 financial performance and the potential
benefits of additional Supervisory Board members. Any
forward-looking statements in this press release are based on
BioNTech’s current expectations and beliefs of future events. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond BioNTech’s control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. You should review the risks and
uncertainties described under the heading “Risk Factors” in
BioNTech’s Annual Report on Form 20-F for the Year Ended December
31, 2021, filed with the SEC on March 30, 2022, which is available
on the SEC’s website at www.sec.gov. All information in this press
release is as of the date of the release, and BioNTech undertakes
no duty to update this information unless required by law.
Media RelationsJasmina Alatovic+49 (0)6131 9084
1513Media@biontech.de
Investor RelationsSylke Maas, Ph.D.+49 (0)6131
9084 1074Investors@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From May 2023 to May 2024